Form 4: NextCure CEO Michael Richman Awarded Stock Options

NextCure's CEO, Michael Richman, was granted 305,500 stock options with a strike price of $0.8048, vesting over a four-year period.

Summary

• Michael Richman, the President and CEO of NextCure, Inc., was granted 305,500 employee stock options on January 31, 2025.
• The exercise price for these options is $0.8048 per share.
• The options vest over a period of four years, with one-fourth vesting on January 31, 2026, and the remainder vesting in 36 monthly installments starting February 28, 2026.
• The options expire on January 30, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively for aligning management and shareholder interests. There are no negative implications.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of four years is also typical, aligning with long-term value creation.
• The exercise price of $0.8048 is a common practice to be at or above the current market price at the time of the grant.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the CEO's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, NextCure, Michael Richman, equity